Last reviewed · How we verify
NCT06992687
A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors
Phase 1, PHASE2 trial testing HB0052 Injection in Solid Tumors in 30 participants. Enrolling by invitation.
30 September 2025
Quick facts
| Lead sponsor | Shanghai Huaota Biopharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 September 2024 |
| Primary completion | 30 September 2025 |
| Estimated completion | 30 November 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- HB0052 Injection — full drug profile →
Conditions studied
- Solid Tumors — all drugs for Solid Tumors →
Sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the safety and tolerability of HB0052 in patients with advanced solid tumors
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06992687
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Tumors
Currently open trials in the same condition.
- NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
- NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
- NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
- NCT07395258 — A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe · Phase 1 · recruiting
- NCT07505069 — Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors · EARLY_PHASE1 · recruiting
Other Shanghai Huaota Biopharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07449156 — A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris. · Phase 1, PHASE2 · not yet recruiting
- NCT07360132 — Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the Fi · Phase 3 · not yet recruiting
- NCT07383116 — Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Li · Phase 3 · not yet recruiting
- NCT06999083 — A Study to Evaluate Single-dose of HB0043 in Healthy Adult Participants · Phase 1 · recruiting
- NCT06895499 — Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients. · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06992687 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Huaota Biopharmaceutical Co., Ltd.
- Last refreshed: 28 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06992687.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing